Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Rapport Therapeutics Inc (NASDAQ: RAPP) closed at $9.99 up 39.72% from its previous closing price of $7.15. In other words, the price has increased by $39.72 from its previous closing price. On the day, 1.24 million shares were traded.
Ratios:
For a deeper understanding of Rapport Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 45.91 and its Current Ratio is at 45.91. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On July 02, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $35.
On July 02, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $35.Jefferies initiated its Buy rating on July 02, 2024, with a $35 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 01 ’24 when HEALY JAMES bought 44,032 shares for $24.52 per share. The transaction valued at 1,079,575 led to the insider holds 40,851 shares of the business.
HEALY JAMES bought 558,824 shares of RAPP for $9,500,008 on Jun 10 ’24. The Director now owns 1,863,327 shares after completing the transaction at $17.00 per share.
Stock Price History:
Over the past 52 weeks, RAPP has reached a high of $29.74, while it has fallen to a 52-week low of $7.13. The 50-Day Moving Average of the stock is -34.31%, while the 200-Day Moving Average is calculated to be -50.79%.
Shares Statistics:
A total of 36.58M shares are outstanding, with a floating share count of 17.47M. Insiders hold about 52.23% of the company’s shares, while institutions hold 54.31% stake in the company.
